You are here: Home » Economy & Policy » News
Business Standard

India's diabetes care market to reach $60 bn in next 10 yrs: Report

The diabetes care market in India is expected to reach about $60 billion in the next 10 years, from approximately $17 billion in FY2021, a new report said

Topics
Diabetes | India | Medicines

IANS  |  Bengaluru 

Fit & Proper: Skin can warn about diabetes

The care market in is expected to reach about $60 billion in the next 10 years, from approximately $17 billion in FY2021, a new report showed on Thursday.

With 75 million diabetic patients, and another 200 million pre-diabetics, is known as the capital of the world.

Poor lifestyle is the prime reason for the rapid increase in cases growth of the market, revealed the study done by Redcore, the research arm of Bengaluru-based research firm Redseer consulting.

According to the report, an average Indian spends Rs 11,000 annually on Type-2 diabetes care and Rs 3.5 lakh in a lifetime.

From Rs 6,000 annually in the early thirties, the cost increases exponentially to Rs 17,000 by the time they reach 60 years of age.

Further, the report showed that only 5 per cent of the diabetic population falls in the average monthly income segment of Rs 80,000 or more, while 35 per cent fall below Rs 20,000.

"Close to 95 per cent of the diabetic population in falls in the middle and low income category and has limited access to diabetes care. It is critical for India to identify a diabetes care solution which is affordable and comprehensive to make it a real success in the country," said Anuj Kumar, director, RedCore, in a statement.

New age tech-based innovations such as connected blood glucose monitoring devices and app based-doctor guidance and coaching are playing a significant role in transforming care in western world.

However, for India to see the adoption of these tech developments at a broad scale, accessibility and affordability will be the key.

The report also observed that within chronic diseases, diabetes (including prediabetes) has the highest prevalence, followed by cardiovascular disease and hypertension in India.

These top three chronic diseases represent a market size of about $35 billion in FY21, and are expected to grow nearly 3 times in the next 10 years, the report said.

--IANS

rvt/na/dpb

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 13 2022. 10:20 IST
RECOMMENDED FOR YOU
.